Literature DB >> 4027947

The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders.

G W Dewald, D J Broderick, W W Tom, J E Hagstrom, R V Pierre.   

Abstract

Bone marrow aspirates from 90 patients suspected of having a hematologic disorder were processed by using different cytogenetic methods to determine if any procedure was more likely to reveal a chromosomally abnormal clone or produce better-quality metaphases. All specimens were processed by a direct technique and 24-hr culture without mitogens; 50 specimens were also processed by an amethopterin mitotic synchronization method. In each case, the microscope slides were coded by the processing technologist and analyzed by two other experienced cytogenetic technologists. The results were not known to any of the investigators until all 90 specimens were analyzed. With the exception of one specimen, in which a chromosomally abnormal clone was identified only in the direct preparation, no apparent differences were found in the karyotypes among the three methods. Also, the differences in the quality or number of metaphases found among the three methods were not statistically significant; however, 24-hr unstimulated cultures produced more metaphases than the mitotic synchronization procedure. The greatest source of discordance was caused by one test yielding either no metaphases or an uncertain result when the other tests produced a successful study. We suggest that in routine practice at least two different methods should be used, and it may be best if at least one of these methods is a direct technique.

Entities:  

Mesh:

Year:  1985        PMID: 4027947     DOI: 10.1016/0165-4608(85)90032-9

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  11 in total

1.  Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.

Authors:  Patrick W Mellors; Moritz Binder; Rhett P Ketterling; Patricia T Greipp; Linda B Baughn; Jess F Peterson; Dragan Jevremovic; Kathryn E Pearce; Francis K Buadi; Martha Q Lacy; Morie A Gertz; Angela Dispenzieri; Suzanne R Hayman; Prashant Kapoor; Wilson I Gonsalves; Yi L Hwa; Amie Fonder; Miriam Hobbs; Taxiarchis Kourelis; Rahma Warsame; John A Lust; Nelson Leung; Ronald S Go; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar
Journal:  Blood Adv       Date:  2020-05-26

2.  Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma.

Authors:  Gordon W Dewald; Terry Therneau; Dirk Larson; You Kyoung Lee; Stephanie Fink; Stephanie Smoley; Sarah Paternoster; Adewale Adeyinka; Rhett Ketterling; Daniel L Van Dyke; Rafael Fonseca; Robert Kyle
Journal:  Blood       Date:  2005-07-19       Impact factor: 22.113

3.  Treatment of marrow stroma with interferon-alpha restores normal beta 1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. Role of MIP-1 alpha.

Authors:  R Bhatia; P B McGlave; C M Verfaillie
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

4.  Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms.

Authors:  Kebede Hussein; Omar Abdel-Wahab; Terra L Lasho; Daniel L Van Dyke; Ross L Levine; Curtis A Hanson; Animesh Pardanani; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

5.  Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.

Authors:  A Tefferi; R L Levine; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; C M Finke; A Mullally; C-Y Li; A Pardanani; D G Gilliland
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

6.  T-lymphocytes with 7;14 translocations: frequency of occurrence, breakpoints, and clinical and biological significance.

Authors:  G W Dewald; K J Noonan; J L Spurbeck; D D Johnson
Journal:  Am J Hum Genet       Date:  1986-04       Impact factor: 11.025

7.  Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

Authors:  D Caramazza; K H Begna; N Gangat; R Vaidya; S Siragusa; D L Van Dyke; C Hanson; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2010-10-14       Impact factor: 11.528

8.  WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.

Authors:  M M Patnaik; T L Lasho; C M Finke; N Gangat; D Caramazza; S G Holtan; A Pardanani; R A Knudson; R P Ketterling; D Chen; J D Hoyer; C A Hanson; A Tefferi
Journal:  Leukemia       Date:  2010-05-20       Impact factor: 12.883

9.  Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?

Authors:  Maura Nicolosi; Mythri Mudireddy; Naseema Gangat; Animesh Pardanani; Curtis A Hanson; Rhett P Ketterling; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-01-12       Impact factor: 11.037

10.  Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.

Authors:  Ayalew Tefferi; Maura Nicolosi; Mythri Mudireddy; Terra L Lasho; Naseema Gangat; Kebede H Begna; Curtis A Hanson; Rhett P Ketterling; Animesh Pardanani
Journal:  Leukemia       Date:  2018-02-02       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.